PharmTech Drug Digest 11.20
News|Articles|September 26, 2017

PTSM: Pharmaceutical Technology Sourcing and Management

  • PTSM: Pharmaceutical Technology Sourcing and Management-10-04-2017
  • Volume 12
  • Issue 10

Cambrex Adds Reactors to Facility in Sweden

Additional reactor capacity and a wastewater processing plant increase API manufacturing capacity at the Cambrex site in Kalskoga, Sweden.

Cambrex Corporation, a manufacturer of small-molecule innovator and generic APIs, announced the completion of an installation of large-scale manufacturing capacity at its cGMP facility in Karlskoga, Sweden. The expansion included multi-purpose reactors ranging from 4–12-cubic meters in size, and a 9-cubic-meter hydrogenation reactor. The company also announced a multi-year construction project to increase the site’s wastewater processing capabilities in a Sept. 26, 2017 press statement.

The waste water treatment plant, designed to support the expansion and improve existing biological processes, is being phased over a three-year period. The $3.5-million (30.5M SEK) investment will process more than 4000 cubic meters of water daily and handle variations in the composition of effluent. The majority of the construction project will be completed in 2017, with additional upgrades in 2018 and 2019, the company reported, and when completed, the facility will reduce the emission of nitrogen, total organic compounds, and suspended material.

“Our Karlskoga site is a crucial part of the company’s global manufacturing network, and these investments, to not only to increase capacity, but also to the supporting infrastructure, will enable the site to work efficiently both now, and into the future,” commented Bjarne Sandberg, managing director, Cambrex Karlskoga.

The expansion at the company’s Swedish site follows the announcement of the construction of a $24-million, 4500-sq.- ft. highly potent API manufacturing facility at in Charles City, IA, which is due to open in 2019.

Source: Cambrex

 


Related to this article

white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.
Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.